Cargando…

Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome()

It is known that Alzheimer's disease (AD) presents at an early age in people with Down syndrome (DS). The trisomy 21 in DS provides an opportunity to study the effect of duplicated genes in AD. APP and BACE2 are 2 genes located in chromosome 21 and related to AD. We looked into our cohort of 67...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mok, Kin Y., Jones, Emma L., Hanney, Marisa, Harold, Denise, Sims, Rebecca, Williams, Julie, Ballard, Clive, Hardy, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Genetic Report Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969241/ https://www.ncbi.nlm.nih.gov/pubmed/24462566 http://dx.doi.org/10.1016/j.neurobiolaging.2013.12.022

Ejemplares similares

Erratum to “Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome” [Neurobiol. Aging 35 (2014) 1513.e1–1513.e5]
por: Mok, Kin Y., et al.
Publicado: (2014)

Erratum to “Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome” [Neurobiol. Aging 35 (2014) 1513.e1–1513.e5]
por: Mok, Kin Y., et al.
Publicado: (2014)

Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome
por: Jones, Emma L., et al.
Publicado: (2013)

An Intron 7 Polymorphism in APP Affects the Age of Onset of Dementia in Down Syndrome
por: Jones, Emma L., et al.
Publicado: (2010)

A tale of two drug targets: the evolutionary history of BACE1 and BACE2
por: Southan, Christopher, et al.
Publicado: (2013)

BACE1 role in Alzheimer's disease and other dementias: from the theory to the practice
por: Cervellati, Carlo, et al.
Publicado: (2021)

Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease
por: Zuliani, Giovanni, et al.
Publicado: (2020)

Early elevation of BACE1 in dementia
por: Cervellati, Carlo, et al.
Publicado: (2021)

Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults
por: Creese, Byron, et al.
Publicado: (2021)

Treatment Modalities for Dementia in Down’s Syndrome: A Literature Review
por: Lamsal Lamichhane, Smriti, et al.
Publicado: (2022)

Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
por: Startin, Carla M., et al.
Publicado: (2019)

Polygenic risk scores for Alzheimer's disease are related to dementia risk in APOE ɛ4 negatives
por: Najar, Jenna, et al.
Publicado: (2021)

Genetic and polygenic risk score analysis for Alzheimer's disease in the Chinese population
por: Zhou, Xiaopu, et al.
Publicado: (2020)

Role of BACE1 in Alzheimer’s synaptic function
por: Das, Brati, et al.
Publicado: (2017)

Tiny Toes to Tau Tangles: Down's Syndrome and Its Association With Alzheimer's Disease
por: Puttagunta, Sri Madhurima, et al.
Publicado: (2022)

Late‐life onset psychotic symptoms and incident cognitive impairment in people without dementia: Modification by genetic risk for Alzheimer's disease
por: Creese, Byron, et al.
Publicado: (2023)

Lipidomics and proteomics: An integrative approach for early diagnosis of dementia and Alzheimer’s disease
por: Tiwari, Virendra, et al.
Publicado: (2023)

MicroRNA-149 is downregulated in Alzheimer’s disease and inhibits β-amyloid accumulation and ameliorates neuronal viability through targeting BACE1
por: Du, Wenyan, et al.
Publicado: (2021)

Aging related cognitive changes associated with Alzheimer's disease in Down syndrome
por: Firth, Nicholas C., et al.
Publicado: (2018)

The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007)

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
por: Coimbra, Judite R. M., et al.
Publicado: (2018)

Post-Translational Modifications of BACE1 in Alzheimer's Disease
por: Wen, Wen, et al.
Publicado: (2022)

Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
por: Hithersay, Rosalyn, et al.
Publicado: (2018)

MiR-29c-3p May Promote the Progression of Alzheimer's Disease through BACE1
por: Cao, Yanqun, et al.
Publicado: (2021)

LRRTM3 Interacts with APP and BACE1 and Has Variants Associating with Late-Onset Alzheimer’s Disease (LOAD)
por: Lincoln, Sarah, et al.
Publicado: (2013)

DHCR7 rs12785878 T>C Polymorphism Is Associated With an Increased Risk of Early Onset of Alzheimer's Disease in Chinese Population
por: Liu, Xixi, et al.
Publicado: (2021)

Heart failure and late-onset Alzheimer’s disease: A Mendelian randomization study
por: Arega, Yibeltal, et al.
Publicado: (2022)

Alzheimer's patient feedback to complement research using model systems for cognitive aging and dementia
por: Murakami, Shin, et al.
Publicado: (2014)

Transcriptome analysis reveals potential marker genes for diagnosis of Alzheimer’s disease and vascular dementia
por: Wang, Li, et al.
Publicado: (2022)

Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease
por: Sassi, Celeste, et al.
Publicado: (2014)

Recent Consanguinity and Outbred Autozygosity Are Associated With Increased Risk of Late-Onset Alzheimer’s Disease
por: Napolioni, Valerio, et al.
Publicado: (2021)

Partial, Rather than Full, BACE1 Inhibition May Be a Better Therapeutic Strategy for Alzheimer’s Disease Due to Effects of Complete Loss of BACE1 Activity on Adult Hippocampal Neurogenesis
por: Carney, Rosalind S.E.
Publicado: (2018)

BACE1, the Alzheimer's beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2012)

BACE1, the Alzheimer’s beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2013)

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
por: Vassar, Robert
Publicado: (2014)

BACE1 inhibition as a therapeutic strategy for Alzheimer's disease
por: Vassar, Robert
Publicado: (2016)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
por: Maia, Miguel A., et al.
Publicado: (2019)

BACE1: from biomarker to Alzheimer’s disease therapeutical target
por: Cervellati, Carlo, et al.
Publicado: (2021)

BACE2: A Promising Neuroprotective Candidate for Alzheimer’s Disease
por: Yeap, Yee Jie, et al.
Publicado: (2023)

ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid-β copathology
por: Koriath, Carolin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gho3t8iv4rm52jgjmt1v7e37fk